XML 31 R21.htm IDEA: XBRL DOCUMENT
v3.23.2

CONCENTRATIONS | 6 Months Ended
--- | ---
Jun. 30, 2023
CONCENTRATIONS |
CONCENTRATIONS | (15) CONCENTRATIONS For the three months ended June 30, 2023, the Company sourced approximately 24% of the supplies for its electrotherapy products from two significant vendors. For the same period in 2022, the Company sourced approximately 58% of the supplies for its electrotherapy products from four significant vendors. For the six months ended June 30, 2023, the Company sourced approximately 26% of supplies for its electrotherapy products from two significant vendors. For the same period in 2022, the Company sourced approximately 53% of supplies for its electrotherapy products from four significant vendors. At June 30, 2023, the Company had no receivables from any third-party payers that made up over 10% of the net accounts receivable balance. At December 31, 2022, the Company had receivables from one third-party payer which made up approximately 14% of the net accounts receivable balance.

X
- Definition The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//275/tableOfContent + Details
Name: | us-gaap_ConcentrationRiskDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RisksAndUncertaintiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration